Business
Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies
Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nCatalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCatalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies\nPR Newswire\nSWINDON, U.K., and LAS VEGAS, Sept. 26, 2018\n\n\n\nGB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson's disease\n SWINDON, U.K., and LAS VEGAS, Sept. 26, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) and Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences' proprietary active pharmaceutical ingredients (\"APIs\") for its Parkinson's disease therapies. A proof of concept study will be conducted by Catalent at its Swindon, U.K. facility to evaluate GB Sciences' clinical candidates GBS101, GBS102, and GBS103 using Catalent's proprietary Zydis® Orally Disintegrating Tablet (ODT) technology.\n\n \n \n\n \nGB Sciences' three patent-pending APIs for Parkinson's disease are complex mixtures containing up to nine individual components that function synergistically. Preclinical studies have shown that these cannabinoid-containing complex mixtures are more potent than would have been predicted by combining the activity of each individual compound.\n\"To prepare our Parkinson's disease formulations for human clinical trials, we wanted the ease-of-use offered by Zydis ODTs for our Parkinson's patients, many of whom may have difficulties in swallowing. Catalent's proprietary delivery method also potentially offers consistent dosing for our complex cannabinoid- and terpenoid-containing APIs,\" explained Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. \"The creation of GB Sciences' proprietary ...